TRIM58

Summary

TRIM58 (tripartite motif containing 58, HGNC:24150) is a protein-coding gene on chromosome 1q44, encoding E3 ubiquitin-protein ligase TRIM58 (Q8NG06). E3 ubiquitin ligase induced during late erythropoiesis.

Predicted to enable ubiquitin protein ligase activity. Predicted to be involved in innate immune response and regulation of gene expression. Predicted to be active in cytoplasm.

Source: NCBI Gene 25893 — RefSeq curated summary.

At a glance

• GWAS associations: 73
• Clinical variants (ClinVar): 79 total
• Druggable target: yes
• MANE Select transcript: NM_015431

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24150
Approved symbol	TRIM58
Name	tripartite motif containing 58
Location	1q44
Locus type	gene with protein product
Status	Approved
Aliases	BIA2
Ensembl gene	ENSG00000162722
Ensembl biotype	protein_coding
OMIM	620527
Entrez	25893

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000366481

RefSeq mRNA: 1 — MANE Select: NM_015431 NM_015431

CCDS: CCDS1636

Canonical transcript exons

ENST00000366481 — 6 exons

Exon	Start	End
ENSE00001067987	247867845	247867867
ENSE00001067990	247864705	247864935
ENSE00001068001	247867963	247868063
ENSE00001278425	247860617	247860712
ENSE00001441819	247875900	247880138
ENSE00001441820	247857187	247857666

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 95.11.

FANTOM5 (CAGE): breadth broad, TPM avg 5.4202 / max 706.2279, expressed in 599 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9632	2.5161	267
9635	1.4508	413
9633	0.5084	229
9636	0.3714	112
9631	0.3339	31
9634	0.1859	98
9638	0.0339	11
9637	0.0196	7

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trabecular bone tissue	UBERON:0002483	95.11	gold quality
monocyte	CL:0000576	94.80	gold quality
mononuclear cell	CL:0000842	94.71	gold quality
leukocyte	CL:0000738	93.40	gold quality
blood	UBERON:0000178	90.02	gold quality
bone marrow	UBERON:0002371	88.16	gold quality
bone marrow cell	CL:0002092	85.98	gold quality
dorsal root ganglion	UBERON:0000044	77.15	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.87	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.97	gold quality
right lobe of thyroid gland	UBERON:0001119	75.20	gold quality
left lobe of thyroid gland	UBERON:0001120	74.75	gold quality
granulocyte	CL:0000094	74.42	gold quality
thyroid gland	UBERON:0002046	74.05	gold quality
cortical plate	UBERON:0005343	71.53	gold quality
trigeminal ganglion	UBERON:0001675	70.49	silver quality
right lung	UBERON:0002167	69.91	gold quality
pons	UBERON:0000988	68.70	gold quality
ganglionic eminence	UBERON:0004023	68.32	gold quality
tibial nerve	UBERON:0001323	66.34	gold quality
placenta	UBERON:0001987	64.98	gold quality
spleen	UBERON:0002106	64.71	gold quality
colonic epithelium	UBERON:0000397	63.27	silver quality
secondary oocyte	CL:0000655	62.91	silver quality
mucosa of transverse colon	UBERON:0004991	62.56	gold quality
ventricular zone	UBERON:0003053	62.26	gold quality
sural nerve	UBERON:0015488	61.35	silver quality
embryo	UBERON:0000922	60.36	gold quality
hypothalamus	UBERON:0001898	59.98	gold quality
testis	UBERON:0000473	59.93	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	1183.49
E-CURD-112	yes	52.33
E-MTAB-9221	yes	19.85
E-HCAD-9	yes	7.51
E-MTAB-9067	no	3.60
E-MTAB-9467	no	2.66
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

134 targeting TRIM58, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-8067	99.86	69.59	2260

Literature-anchored findings (GeneRIF, showing 10)

• Our findings suggest that aberrant inactivation of TRIM58 consequent to CGI hypermethylation might stimulate the early carcinogenesis of LADC regardless of smoking status; furthermore, TRIM58 methylation might be a possible early diagnostic and epigenetic therapeutic target in LADC. (PMID:27926516)
• he present study would help to elucidate the influence of TRIM58/cg26157385 methylation on lung cancer prognosis (PMID:29749538)
• Low TRIM58 expression is associated with colorectal cancer cell invasion. (PMID:29956813)
• Identify TRIM58 as a novel negative mediator of innate immune control and mucosal homeostasis via TLR2 signaling. (PMID:31383741)
• TRIM58 suppresses the tumor growth in gastric cancer by inactivation of beta-catenin signaling via ubiquitination. (PMID:31747856)
• TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells. (PMID:32219144)
• TRIM58 is a prognostic biomarker remodeling the tumor microenvironment in KRAS-driven lung adenocarcinoma. (PMID:33406903)
• [Correlation between the Promoter Methylation Status of TRIM58 and Its mRNA Expression in Acute Myeloid Leukemia]. (PMID:36208235)
• TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation via UPP. (PMID:36644609)
• TRIM58 functions as a tumor suppressor in colorectal cancer by promoting RECQL4 ubiquitination to inhibit the AKT signaling pathway. (PMID:37516854)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Trim58	ENSMUSG00000037124
rattus_norvegicus	Trim58	ENSRNOG00000026430

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890)

Protein

Protein identifiers

E3 ubiquitin-protein ligase TRIM58 — Q8NG06 (reviewed: Q8NG06)

Alternative names: Protein BIA2, RING-type E3 ubiquitin transferase TRIM58, Tripartite motif-containing protein 58

All UniProt accessions (1): Q8NG06

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin ligase induced during late erythropoiesis. Directly binds and ubiquitinates the intermediate chain of the microtubule motor dynein (DYNC1LI1/DYNC1LI2), stimulating the degradation of the dynein holoprotein complex. May participate in the erythroblast enucleation process through regulation of nuclear polarization.

Tissue specificity. Expressed in erythroblasts.

Domain organisation. The RING finger is required for ubiquitin ligase activity.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the TRIM/RBCC family.

RefSeq proteins (1): NP_056246* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000315	Znf_B-box	Domain
IPR001841	Znf_RING	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR003879	Butyrophylin_SPRY	Domain
IPR006574	PRY	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR035787	SPRY/PRY_TRIM58	Domain
IPR042699	TRIM58_RING-HC	Domain
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050143	TRIM/RBCC	Family

Pfam: PF00622, PF00643, PF13765, PF15227

UniProt features (37 total): strand 15, helix 6, binding site 4, sequence variant 3, turn 3, zinc finger region 2, chain 1, domain 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8PD6	X-RAY DIFFRACTION	1.3
8PD4	X-RAY DIFFRACTION	2.71

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NG06-F1	87.32	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 96; 99; 118; 124

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 143 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_NK_CELL_VS_BCELL_DN, GOBP_REGULATION_OF_CELL_MATURATION, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_MYELOID_CELL_DEVELOPMENT, GOBP_ERYTHROCYTE_HOMEOSTASIS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_ORGANELLE_TRANSPORT_ALONG_MICROTUBULE, GOBP_ANATOMICAL_STRUCTURE_MATURATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, GOBP_CELL_MATURATION, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, GOBP_PROTEIN_AUTOUBIQUITINATION

GO Biological Process (8): protein polyubiquitination (GO:0000209), ubiquitin-dependent protein catabolic process (GO:0006511), regulation of gene expression (GO:0010468), innate immune response (GO:0045087), protein autoubiquitination (GO:0051865), positive regulation of erythrocyte enucleation (GO:0061931), regulation of nuclear migration along microtubule (GO:1902838), protein ubiquitination (GO:0016567)

GO Molecular Function (7): zinc ion binding (GO:0008270), dynein heavy chain binding (GO:0045504), dynein intermediate chain binding (GO:0045505), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein ubiquitination	3
protein binding	2
modification-dependent protein catabolic process	1
gene expression	1
regulation of macromolecule biosynthetic process	1
immune response	1
defense response to symbiont	1
erythrocyte enucleation	1
positive regulation of cellular component organization	1
regulation of erythrocyte enucleation	1
nuclear migration along microtubule	1
regulation of organelle transport along microtubule	1
protein modification by small protein conjugation	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

944 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRIM58	OR2W3	Q7Z3T1	746
TRIM58	OR2T8	A6NH00	659
TRIM58	GPATCH4	Q5T3I0	611
TRIM58	ZNF177	Q13360	570
TRIM58	TM6SF1	Q9BZW5	560
TRIM58	CDO1	P78513	521
TRIM58	TENT5C	Q5VWP2	520
TRIM58	CPAMD8	Q8IZJ3	503
TRIM58	UBQLN3	Q9H347	493
TRIM58	RXRB	P28702	467
TRIM58	GRIA2	P42262	457
TRIM58	FAM240A	A0A1B0GVK7	431
TRIM58	BBOX1	O75936	427
TRIM58	MIMS2	Q96KR6	426
TRIM58	TRAT1	Q6PIZ9	415

IntAct

22 interactions, top by confidence:

A	B	Type	Score
SOST	LRP6	psi-mi:“MI:0914”(association)	0.890
PDIK1L	CTDSPL2	psi-mi:“MI:0914”(association)	0.840
NHERF2	PODXL	psi-mi:“MI:0914”(association)	0.770
VASP	CEP43	psi-mi:“MI:0914”(association)	0.740
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
BCL7A	ARID1A	psi-mi:“MI:0914”(association)	0.640
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
HMCES	HSPA8	psi-mi:“MI:0914”(association)	0.640
RNMT	KPNA5	psi-mi:“MI:0914”(association)	0.530
CAVIN1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
CER1	PC	psi-mi:“MI:0914”(association)	0.350
ESS2	CDC40	psi-mi:“MI:0914”(association)	0.350
GOLGA2	UPK2	psi-mi:“MI:0914”(association)	0.350
KPNA2	TAF4	psi-mi:“MI:0914”(association)	0.350
MICB	LGALS8	psi-mi:“MI:0914”(association)	0.350
NELFE	KNOP1	psi-mi:“MI:0914”(association)	0.350
NUP50	MCM3AP	psi-mi:“MI:0914”(association)	0.350
PPFIBP1	OBSL1	psi-mi:“MI:0914”(association)	0.350
TAF7L	KLRG2	psi-mi:“MI:0914”(association)	0.350
TCP10L	DFFA	psi-mi:“MI:0914”(association)	0.350
THAP11	XPC	psi-mi:“MI:0914”(association)	0.350

BioGRID (45): DYNC1H1 (Affinity Capture-Western), DYNC1I1 (Reconstituted Complex), DYNC1I1 (Affinity Capture-Western), DYNC1I1 (Affinity Capture-MS), DYNC2LI1 (Affinity Capture-MS), DYNC1LI2 (Affinity Capture-MS), DYNC1H1 (Affinity Capture-MS), DYNC1I1 (Biochemical Activity), TRIM58 (Biochemical Activity), UBE2D3 (Reconstituted Complex), TRIM58 (Synthetic Lethality), TRIM58 (Two-hybrid), TRIM58 (Affinity Capture-Western), TLR2 (Affinity Capture-Western), TRIM58 (Affinity Capture-Western)

ESM2 similar proteins: A0JN74, A6NCK2, A6NGJ6, A6NI03, B1H278, K7N6K2, O00478, O00481, P14373, P19474, Q13410, Q1ACD5, Q1ACD6, Q1ACD7, Q1ACD8, Q1XHU0, Q2YEM8, Q2YEM9, Q3ZEE5, Q587N6, Q5C8T6, Q5C8T8, Q5C8U1, Q5D7I9, Q5D7J0, Q5D7J1, Q5NCC9, Q5R996, Q62158, Q6MFZ5, Q7YR33, Q7YRV4, Q80V85, Q8BGE7, Q8NG06, Q923T7, Q96BQ3, Q96F44, Q99PP6, Q99PQ2

Diamond homologs: A0A3B3IT33, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NLI5, B0BLU1, C9J1S8, I1YAP6, O00478, O00481, O15344, O75677, O75678, O75679, O76064, P0CI25, P0CI26, P18892, P19474, P62603, P86448, P86449, Q13410, Q2HJ46, Q3C1V9, Q3TL54, Q4KLN8, Q5EBN2, Q5PQN2, Q5R4I2, Q5R996, Q61510, Q62556, Q6INS5, Q6MFY8, Q6UX41, Q6UXE8, Q6ZWI9, Q7T308

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	TRIM58	ubiquitination
TRIM58	“up-regulates activity”	DDX58	ubiquitination
TRIM58	“down-regulates quantity by destabilization”	DYNC1I2	polyubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 41 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Viral Infection Pathways	6	6.8×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	67
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1086 predictions. Top by Δscore:

Variant	Effect	Δscore
1:247862651:C:G	donor_gain	1.0000
1:247864901:A:T	donor_gain	1.0000
1:247867839:TTTCA:T	acceptor_loss	1.0000
1:247867840:TTCA:T	acceptor_loss	1.0000
1:247867841:TCAGG:T	acceptor_loss	1.0000
1:247867842:CAGGG:C	acceptor_loss	1.0000
1:247867843:AG:A	acceptor_gain	1.0000
1:247867844:GG:G	acceptor_gain	1.0000
1:247868053:G:GT	donor_gain	1.0000
1:247875873:ACCT:A	acceptor_gain	1.0000
1:247875876:T:A	acceptor_gain	1.0000
1:247857663:CCAGG:C	donor_loss	0.9900
1:247857664:CAGGT:C	donor_loss	0.9900
1:247857667:G:A	donor_loss	0.9900
1:247857668:T:G	donor_loss	0.9900
1:247860613:ACAG:A	acceptor_loss	0.9900
1:247860614:CAGG:C	acceptor_loss	0.9900
1:247860615:AG:A	acceptor_loss	0.9900
1:247860710:AAGG:A	donor_loss	0.9900
1:247860713:GTA:G	donor_loss	0.9900
1:247860714:T:A	donor_loss	0.9900
1:247862694:G:GG	donor_gain	0.9900
1:247864933:G:GT	donor_gain	0.9900
1:247864935:GG:G	donor_loss	0.9900
1:247864936:G:GC	donor_loss	0.9900
1:247864937:T:A	donor_loss	0.9900
1:247864938:GAG:G	donor_loss	0.9900
1:247867843:A:AG	acceptor_gain	0.9900
1:247867843:AGG:A	acceptor_gain	0.9900
1:247867843:AGGGT:A	acceptor_gain	0.9900

AlphaMissense

3139 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:247857349:T:C	F35L	0.997
1:247857351:C:A	F35L	0.997
1:247857351:C:G	F35L	0.997
1:247857562:T:C	F106L	0.993
1:247857564:C:A	F106L	0.993
1:247857564:C:G	F106L	0.993
1:247857292:T:C	C16R	0.991
1:247857345:C:A	H33Q	0.990
1:247857345:C:G	H33Q	0.990
1:247857346:A:C	S34R	0.990
1:247857348:C:A	S34R	0.990
1:247857348:C:G	S34R	0.990
1:247857350:T:C	F35S	0.989
1:247876013:T:C	F329L	0.989
1:247876015:T:A	F329L	0.989
1:247876015:T:G	F329L	0.989
1:247876070:T:A	W348R	0.986
1:247876070:T:C	W348R	0.986
1:247857352:T:C	C36R	0.985
1:247876072:G:C	W348C	0.984
1:247876072:G:T	W348C	0.984
1:247876110:G:A	G361E	0.982
1:247857415:T:C	C57R	0.981
1:247857563:T:C	F106S	0.981
1:247876100:T:A	W358R	0.981
1:247876100:T:C	W358R	0.981
1:247857328:A:C	S28R	0.980
1:247857330:C:A	S28R	0.980
1:247857330:C:G	S28R	0.980
1:247857354:C:G	C36W	0.980

dbSNP variants (sampled 300 via entrez): RS1000098897 (1:247870282 G>C,T), RS1000136606 (1:247869355 A>G), RS1000152842 (1:247870449 G>A), RS1000156917 (1:247857733 G>A,C,T), RS1000236676 (1:247858350 A>C), RS1000253599 (1:247863835 T>C), RS1000378028 (1:247859665 T>G), RS1000402129 (1:247869593 C>T), RS1000442898 (1:247864583 A>C,G), RS1000521371 (1:247859371 C>T), RS1000616843 (1:247874867 A>G), RS1000630845 (1:247880308 C>G,T), RS1000903102 (1:247875039 G>A,C), RS1000997089 (1:247864945 G>T), RS1001049924 (1:247863550 A>T)

Disease associations

OMIM: gene MIM:620527 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

73 associations (top):

Study	Trait	p-value
GCST000585_13	Mean corpuscular volume	2.000000e-08
GCST001337_5	Platelet count	6.000000e-09
GCST001765_36	Red blood cell traits	5.000000e-10
GCST002712_11	Red blood cell fatty acid levels	5.000000e-11
GCST002868_16	Response to serotonin reuptake inhibitors in major depressive disorder	4.000000e-06
GCST004004_28	Mean corpuscular volume	1.000000e-09
GCST004004_29	Mean corpuscular volume	3.000000e-14
GCST004025_19	Systemic juvenile idiopathic arthritis	3.000000e-06
GCST004335_1	Mean corpuscular volume	4.000000e-06
GCST004599_267	Mean platelet volume	8.000000e-63
GCST004599_268	Mean platelet volume	4.000000e-48
GCST004599_269	Mean platelet volume	2.000000e-62
GCST004601_14	Red blood cell count	1.000000e-29
GCST004602_27	Mean corpuscular volume	2.000000e-63
GCST004603_204	Platelet count	9.000000e-17
GCST004605_57	Mean corpuscular hemoglobin concentration	4.000000e-39
GCST004610_39	White blood cell count	2.000000e-09
GCST004611_3	High light scatter reticulocyte count	1.000000e-86
GCST004611_4	High light scatter reticulocyte count	1.000000e-30
GCST004612_160	High light scatter reticulocyte percentage of red cells	2.000000e-89
GCST004612_161	High light scatter reticulocyte percentage of red cells	1.000000e-22
GCST004615_88	Hemoglobin concentration	1.000000e-09
GCST004616_126	Platelet distribution width	5.000000e-22
GCST004619_100	Reticulocyte fraction of red cells	2.000000e-54
GCST004619_26	Reticulocyte fraction of red cells	1.000000e-208
GCST004621_45	Red cell distribution width	2.000000e-17
GCST004621_46	Red cell distribution width	2.000000e-27
GCST004622_144	Reticulocyte count	2.000000e-54
GCST004622_145	Reticulocyte count	4.000000e-196
GCST004628_138	Immature fraction of reticulocytes	3.000000e-172

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0004305	erythrocyte count
EFO:0006810	oleic acid measurement
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0007986	reticulocyte count
EFO:0004509	hemoglobin measurement
EFO:0007984	platelet component distribution width
EFO:0009188	Red cell distribution width
EFO:0004527	mean corpuscular hemoglobin
EFO:0004587	lymphocyte count
EFO:0010701	mean reticulocyte volume
EFO:0004833	neutrophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465334 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs72772787	TRIM58		0.00	0

ChEMBL bioactivities

4 potent at pChembl≥5 of 9 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.28	EC50	5300	nM	CHEMBL5412814
5.18	EC50	6600	nM	CHEMBL5420185
5.13	EC50	7400	nM	CHEMBL5426823
5.07	EC50	8600	nM	CHEMBL5419488

PubChem BioAssay actives

4 with measured affinity, of 12 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-N-[3-(dimethylamino)propyl]-6-phenyl-4-N-(piperidin-4-ylmethyl)quinazoline-2,4-diamine	2038752: Displacement of Ac-DKSDLKAELERKK-C(BODIPY-FL-M)-RLAQIREEKKRKEE-NH2 peptide probe from TRIM58 (279 to 466 residue) (unknown origin) preincubated for 30 mins followed by probe addition by fluorescence polarization method	ec50	5.3000	uM
6-cyclohexyl-2-N-methyl-4-N-(piperidin-4-ylmethyl)quinazoline-2,4-diamine	2038752: Displacement of Ac-DKSDLKAELERKK-C(BODIPY-FL-M)-RLAQIREEKKRKEE-NH2 peptide probe from TRIM58 (279 to 466 residue) (unknown origin) preincubated for 30 mins followed by probe addition by fluorescence polarization method	ec50	6.6000	uM
2-N-[3-(dimethylamino)propyl]-4-N-hexyl-6-phenylquinazoline-2,4-diamine	2038752: Displacement of Ac-DKSDLKAELERKK-C(BODIPY-FL-M)-RLAQIREEKKRKEE-NH2 peptide probe from TRIM58 (279 to 466 residue) (unknown origin) preincubated for 30 mins followed by probe addition by fluorescence polarization method	ec50	7.4000	uM
2-N-(cyclopropylmethyl)-6-phenyl-4-N-(piperidin-4-ylmethyl)quinazoline-2,4-diamine	2038752: Displacement of Ac-DKSDLKAELERKK-C(BODIPY-FL-M)-RLAQIREEKKRKEE-NH2 peptide probe from TRIM58 (279 to 466 residue) (unknown origin) preincubated for 30 mins followed by probe addition by fluorescence polarization method	ec50	8.6000	uM

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
triphenyl phosphate	affects expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
diallyl trisulfide	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
Sunitinib	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Lead	affects methylation	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Rotenone	decreases expression	1
Silicon Dioxide	increases expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1
Cyclosporine	decreases methylation	1
Copper Sulfate	increases expression	1
Particulate Matter	increases abundance, increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5393140	Binding	Displacement of Ac-DKSDLKAELERKK-C(BODIPY-FL-M)-RLAQIREEKKRKEE-NH2 peptide probe from TRIM58 (279 to 466 residue) (unknown origin) preincubated for 30 mins followed by probe addition by fluorescence polarization method	Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase. — ACS Med Chem Lett

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TU39	HAP1 TRIM58 (-) 1	Cancer cell line	Male
CVCL_TU40	HAP1 TRIM58 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.